Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance
| Title: | Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance |
|---|---|
| Authors: | Andrey S. Shkoda; Vladimir A. Gushchin; Darya A. Ogarkova; Svetlana V. Stavitskaya; Olga E. Orlova; Nadezhda A. Kuznetsova; Elena N. Keruntu; Andrei A. Pochtovyi; Alexander V. Pukhov; Denis A. Kleymenov; Vasyli G. Krzhanovsky; Daria V. Vasina; Nataliya V. Shkuratova; Elena V. Shidlovskaya; Alexey L. Gorbunov; Daria D. Kustova; Evgeniya A. Mazurina; Sofya R. Kozlova; Alexandra V. Soboleva; Igor V. Grigoriev; Lyudmila L. Pankratyeva; Alina S. Odintsova; Elizaveta D. Belyaeva; Arina A. Bessonova; Lyudmila A. Vasilchenko; Igor P. Lupu; Ruslan R. Adgamov; Artem P. Tkachuk; Elizaveta A. Tokarskaya; Denis Y. Logunov; Alexander L. Gintsburg |
| Source: | Vaccines, Vol 10, Iss 938, p 938 (2022) |
| Publisher Information: | MDPI AG |
| Publication Year: | 2022 |
| Collection: | Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: | COVID-19; SARS-CoV-2; vaccine; Sputnik V; Sputnik Light; VOC; Medicine |
| Description: | Mass vaccination campaigns against COVID-19 affected more than 90% of the population in most developed countries. The new epidemiologic wave of COVID-19 has been ongoing since the end of 2021. It is caused by a virus variant B.1.1.529, also known as “Omicron” and its descendants. The effectiveness of major vaccines against Omicron is not known. The purpose of this study is to evaluate the efficacy of the Sputnik V vaccine. The main goal is to assess its protection against hospitalization in the period of Omicron dominance. We conducted our study based on a large clinical center in Moscow (Russia) where 1112 patients were included. We used the case-population method to perform the calculations. The data we obtained indicate that the Omicron variant causes at least 90% of infections in the studied cohort. The effectiveness of protection against hospitalization with COVID-19 in our study was 85.9% (95% CI 83.0–88.0%) for those who received more than one dose. It was 87.6% (95% CI 85.4–89.5%) and 97.0% (95% CI 95.9–97.8%) for those who received more than two or three doses. The effectiveness in cases of more severe forms was higher than for less severe ones. Thus, present study indicates the high protective efficacy of vaccination against hospitalization with COVID-19 in case of Omicron lineage. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | https://www.mdpi.com/2076-393X/10/6/938; https://doaj.org/toc/2076-393X; https://doaj.org/article/c4744e9555854b4a91673a7c0e884fca |
| DOI: | 10.3390/vaccines10060938 |
| Availability: | https://doi.org/10.3390/vaccines10060938; https://doaj.org/article/c4744e9555854b4a91673a7c0e884fca |
| Accession Number: | edsbas.E3939289 |
| Database: | BASE |